REG - GENinCode PLC - Notice of Results

GenincodeAnnouncement

22/05/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260522:nRSV3224Fa&default-theme=true

RNS Number : 3224F  GENinCode PLC  22 May 2026

22 May 2026

GENinCode Plc

("GENinCode" or the "Company")

 

Notice of results

Analyst and investor briefing

 

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused
on the prevention of cardiovascular disease and ovarian cancer, announces that
it will release its audited final results for the year ended 31 December 2025
on Monday, 8 June 2026.

 

Analyst briefing

A briefing open to equity research analysts will take place on Monday 8 June
2026 at 09.30am BST. To register and for more details please contact Walbrook
PR on genincode@walbrookpr.com (mailto:genincode@walbrookpr.com) .

 

Investor presentation

Matthew Walls, Chief Executive Officer, and Paul Foulger, Chief Financial
Officer, will provide a live presentation relating to the results via the
Investor Meet Company platform on Wednesday, 10 June at 11am BST.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via the Investor Meet Company dashboard until 9am
the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet
GENinCode here
(https://www.investormeetcompany.com/genincode-plc/register-investor) .
Investors who already follow GENinCode on the Investor Meet Company platform
will automatically be invited.

 

For more information visit www.genincode.com (http://www.genincode.com)

 

Enquiries:

 

 GENinCode Plc                      www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO
 Paul Foulger, CFO

 Cavendish Capital Markets Limited  Tel: +44 (0)20 7397 8900
 Giles Balleny / Trisyia Jamaludin (Corporate Finance)
 Harriet Ward (Corporate Broking)
 Nigel Birks (Specialist Sales)

 Walbrook PR Limited                                                  Tel: 020 7933 8780 or genincode@walbrookpr.com
                                                                      (mailto:genincode@walbrookpr.com)
 Anna Dunphy

 

About GENinCode:

 

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease. Cardiovascular disease is the leading cause of death
and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U,
and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventative care and treatment strategies. GENinCode CE marked
invitro-diagnostic molecular tests combine clinical algorithms and
bioinformatics to provide advanced patient risk assessment to predict
cardiovascular disease.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORABMBTMTJTBLF



            Copyright 2019 Regulatory News Service, all rights reserved